# Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)

> **NCT01069770** · PHASE2 · UNKNOWN · sponsor: **Korean Urological Oncology Society** · enrollment: 32 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Metastasis

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01069770
- **Lead sponsor:** Korean Urological Oncology Society
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-07
- **Primary completion:** 2011-12
- **Final completion:** 2012-06
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2011-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01069770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01069770, "Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01069770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*